Altimmune, Inc. Announces Virtual R&D Day Focused on Pemvidutide Development and Upcoming Trial Data

Altimmune will host a virtual R&D Day on March 13, 2025, presenting pemvidutide's development in obesity and MASH.

Quiver AI Summary

Altimmune, Inc. announced a virtual R&D Day scheduled for March 13, 2025, at 12:00 pm Eastern Time, where Key Opinion Leaders will present on the development of pemvidutide, a dual receptor agonist for obesity, MASH, and other indications. The presentations will cover the scientific basis for pemvidutide, clinical data to date, and future development plans, including anticipated topline results from the Phase 2b IMPACT trial in MASH, expected in the second quarter of 2025. The event will be accessible online, and more information about Altimmune and its work is available on its website.

Potential Positives

• Altimmune will host a virtual R&D Day to showcase scientific advancements and clinical data for pemvidutide, enhancing visibility and engagement with stakeholders.
• The presentation will feature Key Opinion Leaders (KOLs), which could validate and elevate the company's credibility in the fields of obesity and MASH.
• Upcoming topline data readout from the Phase 2b trial in MASH is expected in the second quarter of 2025, indicating progress and potential milestones for the company's clinical pipeline.

Potential Negatives

• None

FAQ

What is the date and time of Altimmune's virtual R&D Day?

Altimmune's virtual R&D Day is scheduled for March 13, 2025, at 12:00 pm Eastern Time.

Where can I join the Altimmune R&D Day event?

The R&D Day can be accessed at https://investorday.altimmune.com and on the Events section of Altimmune's website.

What will be covered during the R&D Day presentations?

The presentations will cover the scientific rationale, clinical data, and development plans for pemvidutide across multiple indications.

What is pemvidutide used for?

Pemvidutide is a GLP-1/glucagon dual receptor agonist being developed for obesity, MASH, and other indications.

When is the topline data readout from the IMPACT trial expected?

The topline data readout from the IMPACT trial is expected in the second quarter of 2025.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$ALT Hedge Fund Activity

We have seen 88 institutional investors add shares of $ALT stock to their portfolio, and 89 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• AMERIPRISE FINANCIAL INC added 1,378,854 shares (+35.6%) to their portfolio in Q4 2024, for an estimated $9,941,537
• CAPITAL FUND MANAGEMENT S.A. removed 726,829 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $5,240,437
• BLACKROCK, INC. added 693,211 shares (+12.7%) to their portfolio in Q4 2024, for an estimated $4,998,051
• VANGUARD GROUP INC removed 552,246 shares (-11.1%) from their portfolio in Q4 2024, for an estimated $3,981,693
• READYSTATE ASSET MANAGEMENT LP removed 486,738 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $2,988,571
• UBS GROUP AG added 437,100 shares (+154.8%) to their portfolio in Q4 2024, for an estimated $3,151,491
• SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 426,043 shares (-46.0%) from their portfolio in Q4 2024, for an estimated $3,071,770

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

GAITHERSBURG, M.D., March 06, 2025 (GLOBE NEWSWIRE) --

Altimmune, Inc.

(Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will host a virtual R&D Day on Thursday, March 13, 2025 beginning at 12:00 pm Eastern Time.

The event will include presentations from renowned Key Opinion Leaders (KOLs) in obesity, MASH and each of the two additional indications, covering the scientific rationale for pemvidutide in each indication, clinical data generated to-date and plans for the continued development of pemvidutide, including the upcoming topline data readout from IMPACT, the Company’s Phase 2b trial in MASH, which is expected in the second quarter of 2025.

The event will be available at

https://investorday.altimmune.com

and via the

Events

section of the Altimmune website.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH and other indications. For more information, please visit

www.altimmune.com

.

Follow @Altimmune, Inc. on



LinkedIn





Follow @AltimmuneInc on



Twitter

Company Contact:



Greg Weaver


Chief Financial Officer


Phone: 240-654-1450



ir@altimmune.com

Investor Contact:



Lee Roth


Burns McClellan


Phone: 646-382-3403



lroth@burnsmc.com

Media Contact:



Danielle Cantey


Inizio Evoke, Biotech


Phone: 619-826-4657



danielle.cantey@inizioevoke.com

This press release was published by a CLEAR® Verified individual.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.